Evaluation of prognostic factors of esophageal squamous cell carcinoma (Stage II-III) after concurrent chemoradiotherapy using biopsy specimens

Japanese Journal of Clinical Oncology

Volumn 37, Issue 8, 2007, Pages 583-589

  Kii, Takayuki ^a   Takiuchi, Hiroya ^a   Kawabe, Shinichiro ^a   Gotoh, Masahiro ^a   Ohta, Shunsuke ^a   Tanaka, Toshimitsu ^a   Kuwakado, Shin ^a   Nishitani, Hitoshi ^a   Katsu, Ken Ichi ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Chemoradiotherapy; Esophageal squamous cell carcinoma; Overall survival; PCNA

Indexed keywords

ANTIEMETIC AGENT; BIOLOGICAL MARKER; CISPLATIN; CYCLIN D1; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; PROTEIN P53; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; DRUG WITHDRAWAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GASTROSTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; CYCLIN D1; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESOPHAGEAL NEOPLASMS; ETOPOSIDE; FEMALE; FLUOROURACIL; HUMANS; MALE; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 44849105559     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym077     Document Type: Article

References (32)

1. Fujita H. Present status of esophageal cancer and its treatment in Japan. Ann Thorac Cardiovasc Surg 2004;10(3):135-9.
2. Isono K, Sato H, Nakayama K. Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology 1991;48(5):411-20.
3. Kato H, Watanabe H, Tachimori Y, Iizuka T. Evaluation of neck lymph node dissection for thoracic esophageal carcinoma. Ann Thorac Surg 1991;51(6):931-5.
4. Kato H. Lymph node dissection for thoracic esophageal carcinoma. Two- and 3-.eld lymph node dissection. Ann Chir Gynaecol 1995;84(2):193-9.
5. Coia LR, Engstrom PF, Paul A. Nonsurgical management of esophageal cancer: Report of a study of combined radiotherapy and chemotherapy. J Clin Oncol 1987;5(11):1783-90.
6. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281(17):1623-7.
7. Al-Sarraf M, Pajak TF, Marcial VA, Mowry P, Cooper JS, Stetz J, et al. Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG Study. Cancer 1987;59(2):259-65.
8. Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999;17(9):2915-21.
9. Roth JA, Putnam JB, Jr. Surgery for cancer of the esophagus. Semin Oncol 1994;21(4):453-61.
10. Baba M, Aikou T, Yoshinaka H, Natsugoe S, Fukumoto T, Shimazu H, et al. Long-term results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann Surg 1994;219(3):310-6.
11. Fujita H, Kakegawa T, Yamana H, Shima I, Toh Y, Tomita Y, et al. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg 1995;222(5):654-62.
12. Kato H, Tachimori Y, Watanabe H, Iizuka T. Evaluation of the new (1987) TNM classification for thoracic esophageal tumors. Int J Cancer 1993;53(2):220-3.
13. Hironaka S, Ohtsu A, Boku N, Muto M, Nagashima F, Saito H, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2003;57(2):425-33.
14. Bonnetain F, Bouche O, Michel P, Mariette C, Conroy T, Pezet D, et al. A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer. Ann Oncol 2006;17(5):827-34.
15. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23(10):2310-7.
16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70.
17. Aloia TA, Harpole DH, Jr., Reed CE, Allegra C, Moore MB, Herndon JE, 2nd, et al. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 2001;72(3): 859-66.
18. Gibault L, Metges JP, Conan-Charlet V, Lozac'h P, Robaszkiewicz M, Bessaguet C, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 2005;93(1):107-15.
19. Yasunaga M, Tabira Y, Kondo K, Okuma T, Kitamura N. The prognostic significance of cell cycle markers in esophageal cancer after neoadjuvant chemotherapy. Dis Esophagus 1999;12(2):120-7.
20. Kinugasa S, Tachibana M, Hishikawa Y, Abe S, Yoshimura H, Monden N, et al. Prognostic significance of proliferating cell nuclear antigen (PCNA) in squamous cell carcinoma of the esophagus. Jpn J Clin Oncol 1996;26(6):405-10.
21. Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000;6(3):1161-8.
22. Samejima R, Kitajima Y, Yunotani S, Miyazaki K. Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma. Anticancer Res 1999;19(6C):5515-21.
23. Itami A, Shimada Y, Watanabe G, Imamura M. Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer. Oncology 1999;57(4):311-7.
24. Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: A Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 2001;31(9):419-23.
25. Yano H, Shiozaki H, Kobayashi K, Yano T, Tahara H, Tamura S, et al. Immunohistologic detection of the epidermal growth factor receptor in human esophageal squamous cell carcinoma. Cancer 1991;67(1):91-8.
26. Itakura Y, Sasano H, Shiga C, Furukawa Y, Shiga K, Mori S, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994;74(3):795-804.
27. Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 1998;4(6):1469-74.
28. Samejima R, Kitajima Y, Yunotani S, Miyazaki K. Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma. Anticancer Res 1999;19(6C):5515-21.
29. Hickey K, Grehan D, Reid IM, O'Briain S, Walsh TN, Hennessy TP. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 1994;74(6):1693-8.
30. Jain S, Filipe MI, Hall PA, Waseem N, Lane DP, Levison DA. Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol 1991;44(8):655-9.
31. Okuno Y, Nishimura Y, Kashu I, Ono K, Hiraoka M. Prognostic values of proliferating cell nuclear antigen (PCNA) and Ki-67 for radiotherapy of oesophageal squamous cell carcinomas. Br J Cancer 1999;80(3-4):387-95.
32. Goukon Y, Sasano H, Nishihira T, Nagura H, Mori S. p53 overexpression in human esophageal carcinoma: A correlation with tumor DNA ploidy and two parameter flow cytometric study. Anticancer Res 1994;14(3B):1305-12.